Publications by authors named "S Cappuyns"
Background & Aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit versus resistance to atezo+bev.
View Article and Find Full Text PDFHepatocellular carcinoma presents strong sexual dimorphism, being 2-3 times more frequent in males than in females; however, the role of sex in response to immunotherapies in HCC remains unknown. We demonstrate that NOTCH1, an understudied oncogene in HCC, elicits sexually dimorphic anti-tumor immunity and response to FDA-approved immunotherapies. Surprisingly, males harboring NOTCH1-driven tumors displayed enhanced anti-tumor immune responses, which, in mice, were mediated by dendritic and T cells.
View Article and Find Full Text PDFArticle Synopsis
- TGF-β is implicated in promoting cancer development, and the study investigates a specific protein's role in hepatocellular carcinoma (HCC), finding its overexpression linked to aggressive cancer features.
- The research involved analyzing tumor data from a large number of HCC patients and using mouse models to explore molecular effects, revealing a connection between the protein’s levels and immune system suppression.
- The findings suggest that overexpressing this protein contributes to tumor growth and poor patient outcomes, highlighting its potential as a target for cancer treatment.
Background: Immune checkpoint inhibitors (ICIs) are standard therapy for unresectable HCC, but many patients do not respond. Non-viral HCC, particularly non-alcoholic steatohepatitis (NASH), have been implicated in ICI resistance.
Methods: We reviewed 288 patients with unresectable HCC who received ICI from 1/2017 to 12/2021.
Background: About one third of patients with deficient mismatch repair/microsatellite instability-high metastatic colorectal cancer (dMMR/MSI-H mCRC) experience primary resistance or early progression on immune checkpoint inhibitors (ICI), while others benefit from exceptionally long-lasting responses. In this single-centre retrospective study, we aimed to identify variables associated with improved overall survival (OS) as well as early disease progression.
Methods: All dMMR/MSI-H mCRC patients treated with ICI between 2014 and 2022 were included.